Skip to main content
Premium Trial:

Request an Annual Quote

IGA Licenses KeyGene's Sequence-based Genotyping Technology

NEW YORK (GenomeWeb) – IGA Techology Services has licensed KeyGene's sequence-based genotyping technology for use in certain fields, the firms said today.

As part of the deal, IGA has gained a non-exclusive license for the commercial offering and use of KeyGene's technology, which includes restriction-site-associated DNA sequencing, genotyping-by-sequencing, and related methods for discovering and scoring genetic markets without genome sequence information. The firms said that the technology provides a "very powerful" method of characterizing breeding germplasm diversity and developing markers for improving agronomic traits.

Financial and other terms of the agreement were not disclosed.

KeyGene CSO Michiel van Eijk said in a statement that the ability to carry out genetic biomarker discovery and genotyping simultaneously is gaining widespread use in "a huge range of species" and today's deal "accelerates the genetic improvement of our crops, farm animals, and microorganisms."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.